Character Biosciences

Jersey City, NJ · Founded 2018 · Privately Held (backing)

Developer of precision medicine designed to transform drug development for progressive, polygenic diseases. Character Biosciences is based in Jersey City, NJ and was founded in 2018. It was valued at $203 million at its later-stage round in Sep 2025, the last priced event on record. It has raised $137 million across 2 recorded rounds; the latest was an $8.9 million early-stage round in Sep 2025.

PMV mark · valuation
$203.0M
Oct 2026
Priced at
its later-stage round
Sep 2025
Total raised
$136.9M
Last round
Early Stage VC
Sep 2025

Who backs Character Biosciences?

18 investors
InvestorType
Industry VenturesVenture capital
Innovation EndeavorsVenture capital
Catalio Capital ManagementVenture capital
S32Venture capital
Duke Capital PartnersVenture capital
Casdin CapitalVenture capital
Neman VenturesVenture capital
Lifeforce CapitalVenture capital
EGR PartnersFamily office
Bausch + Lomb—
+ 8 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Character Biosciences investors

18 investors are on record for Character Biosciences, including Industry Ventures, Innovation Endeavors, Catalio Capital Management and S32. By type, the record holds 8 venture capital firms and 1 family office. The early-stage round in Sep 2025 drew 4 investors.

Free account
More of Character Biosciences with a free account
  • ·The complete investor list: 18 names
  • ·Watch Character Biosciences: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 18 firms already write checks for companies like Character Biosciences. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View